You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development and validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 103

    Project Summary Sanfilippo disease (mucopolysaccharidosis type III; MPS III) is a devastating neurodegenerative lysosomal storage disorder of childhood whose pathologic features are neurologic: slowing of development, severe behavioral problems, progressive cognitive decline, dementia, and decline in motor skills leading to immobility, unresponsiveness, and death. We have focused on MPS IIID cause ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds

    SBC: FirstString Research, Inc            Topic: NIDDK

    Project Summary/Abstract According to the ADA, 25.8 million children and adults have diabetes. Diabetics have an increased risk of complications such as heart disease and are prone to impaired wound healing. A major cause of morbidity and hospitalizationis diabetic foot ulceration (DFUs) that may result in infection, gangrene, amputations requiring prolonged hospitalization, costly treatments, an ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds

    SBC: FirstString Research, Inc            Topic: 200

    DESCRIPTION provided by applicant According to the ADA million children and adults have diabetes Diabetics have an increased risk of complications such as heart disease and are prone to impaired wound healing A major cause of morbidity and hospitalization is diabetic foot ulceration DFUs that may result in infection gangrene amputations requiring prolonged hospitalization costly tr ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis

    SBC: Innovimmune Biotherapeutics Holding, LLC            Topic: NIAID

    DESCRIPTION provided by applicant There are unmet medical needs in the limited biologic therapeutics for adults with rheumatoid arthritis RA associated with $ billion annual US health care and societal costs These are due to inadequate efficacy prohibitive costs poor adherence and safety issues infections andamp malignancies Oral small molecule based therapies are warranted due to ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Molecular Diagnostic Test for Early Onset of Lyme disease

    SBC: Bioscience Development Inc            Topic: NIAID

    Project Summary/Abstract There is no validated assay to reliably detect the early onset of the Lyme disease infection at the time when antibiotic therapy has the best chance of a cure without sequelae. Diagnosis is often difficult because most symptoms are often nebulous, with the telltale “bulls-eye” rash only appearing and clearly recognizable in approximately half of cases. The standard typ ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Painless Defibrillation

    SBC: Coridea, LLC            Topic: NHLBI

    Project SummaryThe purpose of the proposed work is first-in-man testing of novel painless defibrillation (PaDe) therapy. Sudden cardiac arrest (SCA) remains the number one killer in western civilization. The underlying mechanism of SCA is usually ventricular fibrillation (VF), and survival depends on prompt defibrillation. Existing defibrillators rely on the delivery of a brief high voltage shock ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Anti-ceramide scFv as Mitigator of the Radiation GI Syndrome

    SBC: Ceramedix Holding, LLC            Topic: NIAID

    Project Summary/Abstract Inhibition of ceramide protects mice from death from the Radiation GI Syndrome (RGS). Administration of anti- ceramide single-chain Fv (scFv) 24 h post radiation exposure increases survival in intestinal stem cells and dramatically improves overall survival in mice. These data indicate that anti-ceramide scFv represents the first effective mitigator of lethal RGS. To advan ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. The Potential to Immunocloak Renal Allografts

    SBC: BREONICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The focus of this project is a novel immunomodifying therapy that provides protection from early allograft rejection in the absence of the standard toxic systemic immunosuppressive drug regimens This novel therapy is a nano barrier membrane called NB LVF consisting of a matrix made of laminin vitrogen fibronectin and type IV collagen NB LVF is applied to ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA

    SBC: Calder Biosciences Inc.            Topic: NIA

    An Influenza pandemic remains an acute threat to world health; and stockpiling a universally protective Influenza vaccine provides a strong defense against this potential catastrophe. The hemagglutinin (HA) protein is the primary target of humoral Ab responses to Influenza; the majority of broadly protective mAbs (bnAbs) against influenza isolated from humans recognize conserved and conformation-s ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis

    SBC: GLYCOMIRA, LLC            Topic: NIAID

    PROJECT SUMMARY Chronic rhinosinusitis (CRS) is one of the most prevalent inflammatory diseases in the U.S., affecting up to 16% of the population and substantially diminishing the quality of life and productivity of patients. In four years, the annual U.S. health care expenditure to treat patients with CRS dramatically increased from $9B to $64B (5% of the health care budget), with a correspondin ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government